Silence Therapeutics Highlights Follow-Up Data at EHA 2026 Demonstrating Durable Efficacy and Potential Best-in-Class Profile for Divesiran in Polycythemia Vera

Contributed by: Business Wire

Logo

Tags

Cardiology

Biotechnology

Pharmaceutical

Oncology

Health

FDA

Genetics

Clinical Trials

Silence Therapeutics plc

More Like This

Silence Therapeutics Presents Additional Phase 1 Data Highlighting Promise of Divesiran as the Potential First-in-Class siRNA Treatment for Polycythemia Vera

Silence Therapeutics Announces Positive Results from Ongoing SANRECO Phase 1 Study of Divesiran in Polycythemia Vera Patients

Silence Therapeutics Completes Enrollment in SANRECO Phase 2 Study of Divesiran for Polycythemia Vera (PV)

Silence Therapeutics Presents Promising Phase 1 Data in Polycythemia Vera Patients at the American Society of Hematology (ASH) Annual Meeting

Silence Therapeutics Highlights Recent Business Achievements and Reports First Quarter 2026 Financial Results

Silence Therapeutics Highlights Recent Business Achievements and Reports Fourth Quarter and Full Year 2025 Financial Results

Silence Therapeutics Reports Second Quarter 2025 Financial Results and Recent Business Highlights

Silence Therapeutics Reports Third Quarter 2025 Financial Results and Recent Business Highlights